Dr. Sarah Chahine

Emerging Markets Leader for Clinical Sequencing Division

Thermo Fisher Scientific

Predictive Genomics & PersonalisedMedicine -A Vision From ThermoFisher Scientific

Abstract:

Healthcare systems around the world are under pressure to fight the rise of non-communicable diseases (NCDs), like cancer. There has been very little innovation in prevention of NCDs, while on the diagnostic side innovative tools have revolutionised patients' lives. Can we leverage genomics to prevent incidence of NCDs and improve diagnosis at global level? If yes, how? The presentation will provide the perspectives of Thermo Fisher Scientific on the future of predictive genomics and personalised medicine.

Biography:

Sarah Chahine is the Emerging Markets Leader for Clinical Sequencing Division at ThermoFisher Scientific. Sarah has started her career in Canada, where she gained extensive research expertise in molecular genetics and genomics working at McMaster University. Sarah obtained a PhD researching mechanisms of molecular biology and physiology and has published a number of scientific articles related to her work. Afterwards she joined ThermoFisherScientific in Canada and USA, where she specialized in Human Genetics disorders. Her Focus was in Genome studies: Gene Expression using QPCR, Genetic Sequencing using Sanger Sequencing and Next Generation Sequencing (NGS). Then moved to Germany to work with Centogeneas the General Manager for Middle East and North Africa. She managed the portfolio for genetic testing for rare genetic disorders for three years. At her current role, She focuses on NGS products that supports Genetic disorders, infectious disease, Reproductive Health and Oncology using Next Generation Sequencing.